Zolbetuximab represents the exciting treatment strategy for people suffering from specific types of colorectal disease. The specific antibody selectively targets glypican-3 (GPC3), a protein frequently present in high amounts on malignant cells in the portion of bowel cancers. Early patient research suggested encouraging results, mainly in patients